Skip to Content

Qiagen NV QGEN Stock Quote

| Rating as of

Morningstar‘s Stock Analysis QGEN

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Reducing Qiagen's Uncertainty Rating In Line With Life Sciences/Diagnostic Peers

Julie Utterback, CFA Senior Equity Analyst

Business Strategy and Outlook

| Julie Utterback, CFA |

Qiagen aims to help scientists and caregivers use biological samples to identify and solve problems related to DNA, RNA, and proteins, and these tools remain in high demand as the COVID-19 pandemic grinds on further. Qiagen's roots are in products that help scientists prepare biological samples for various experiments, and sample preparation products still accounted for 38% of sales in 2021, although slightly inflated as a percentage of sales due to the COVID-19 health crisis. Qiagen remains the undisputed leader in this niche, and we expect Qiagen to continue to invest to maintain that position, despite that end market's ongoing growth prospects in the low single digits.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics QGEN

Company Profile QGEN

Business Description

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (45% of 2021 sales), followed by EMEA (36%) and Asia-Pacific (19%).

Hulsterweg 82
Venlo, 5912 PL, Netherlands
T +31 773556600
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 6,100